PBA
LENZ

Paradigm Biocapital Advisors’s LENZ Therapeutics LENZ Stock Holding History

Paradigm Biocapital Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,073,461
Closed -$50M – 44
2025
Q3 		$50M Sell
1,073,461
-643,605
-37% -$23.7M 1.42% 21
2025
Q2 		$50.3M Buy
1,717,066
+205,134
+14% +$5.58M 2.15% 14
2025
Q1 		$38.9M Buy
1,511,932
+741,477
+96% +$18.3M 1.78% 13
2024
Q4 		$22.2M Buy
+770,455
New +$23.5M 0.77% 25

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Paradigm Biocapital Advisors's LENZ Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 1,073,461 shares — an estimated $50M sold.

Paradigm Biocapital Advisors first reported a position in LENZ in Q4 2024 and held it in 4 quarters. The position peaked at $50.3M in Q2 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,073,461 LENZ Therapeutics shares in Q4 2025, an estimated $50M.
  • Paradigm Biocapital Advisors first reported a position in LENZ Therapeutics in Q4 2024 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's LENZ Therapeutics position peaked at $50.3M in Q2 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.